A diagnosis of keratoconus is scary for anyone, but maybe more so for young people who notice their vision getting worse. Fortunately, a modern treatment called corneal collagen cross-linking (CXL) can help strengthen the cornea and prevent further progression of the disease. In October 2025, the FDA approved Epioxa, a new form of corneal cross-linking that does not require removing the cornea’s outer epithelial layer. This innovation has generated buzz because it improves patient comfort and recovery time.

Epioxa compare vs. traditional epithelium-off (epi-off) cross-linking?

• Which is more effective?
• What does insurance cover? And why would a patient pay more out of pocket for a treatment that is covered by insurance?
• What does the treatment involve?
• What’s the recovery like?
• What’s the long-term follow up and prognosis?

At SHARPEVISION, we believe patients need to understand the medical and financial considerations before choosing treatment.

What Is Keratoconus?

If you’re reading this, you likely already know that keratoconus is a progressive eye condition in which the cornea stretches, and gradually becomes thinner, weaker, and more cone-shaped. Take-home Message: Don’t rub your eyes! As the cornea changes shape, it creates irregular astigmatism, resulting in blurred or distorted vision, glare, halos, and difficulty seeing clearly even with glasses.
Keratoconus often begins during the teenage years or early adulthood. Progression is generally more rapid in younger patients, but can progress at any age. Genetics, abnormal collagen structure, allergies, and especially chronic eye rubbing may contribute to the condition. Keratoconus also involves changes in corneal enzymes, oxidative stress, and inflammatory signaling that can weaken the tissue.
Historically, patients with advanced keratoconus sometimes required a corneal transplant to restore useful vision. Cross-linking has dramatically reduced the need for corneal transplant surgery, which has prevented countless patients from vision impairment and loss. Corneal cross-linking is intended to stabilize the cornea, not to eliminate the need for glasses or contact lenses.

What Is Corneal Cross-Linking?

The cornea gets its strength from an organized collagen fiber structure. Think of “plywood” where there are multiple thin sheets glued together to create a very strong structure. If there’s not enough “glue” between the layers, they can slide over one another, and that’s not good in your house or your cornea. It should be strong and stable.

• Corneal cross-linking uses three essential components:
• Riboflavin (vitamin B2): A photosensitizing medication that absorbs ultraviolet light.
• Ultraviolet-A (UVA) light: Activates the riboflavin to form free radicals
• Oxygen: Participates in the chemical reactions that strengthen the corneal tissue.

With UVA light on the cornea, it activates the riboflavin solution and creates molecular bonds, or “glue” between the collagen layers. The cornea is then strengthened, which slows or stops the progress of stretching and thinning of the cornea.

Traditional Epithelium-Off Cross-Linking: The Established Approach

Traditional epi-off cross-linking has been performed since the early 2000s and has a substantial body of clinical research supporting its effectiveness. During treatment, the surgeon removes the central area of the corneal epithelium (skin) covering the cornea. With the epithelium removed, the riboflavin can penetrate into the underlying corneal stroma, the body of the cornea, which makes up about 90% of the corneal thickness. After the cornea is saturated with riboflavin, a specific dose of ultraviolet light UVA light is applied. The epithelium regrows over the surface of the eye in 3-5 days, but vision recovers over 6-8 weeks.

Advantages of Epi-Off Cross-Linking

Extensive long-term evidence: Epi-off cross-linking has demonstrated durable stabilization of keratoconus in studies extending beyond 10 years.

Reliable riboflavin penetration: The corneal epithelium does its job well-it’s a very strong barrier to protect the body of the cornea. Removing the epithelium allows penetration of riboflavin into the corneal stroma.

Established treatment protocols: Physicians have extensive experience with the procedure and its expected outcomes.

Potential long-term benefits: Successful stabilization can reduce the likelihood of progressive corneal distortion and the eventual need for transplantation.

Disadvantages of Epi-Off Cross-Linking

The main disadvantage is the time to vision recovery, but it’s also uncomfortable for 2-3 days while the epi is off. At SHARPEVISION, we have many ways to make it more comfortable, but it’s still a pain. Patients commonly experience discomfort, tearing, light sensitivity, and blurry vision for days to weeks after treatment. We place a contact lens for 5 days to act like a bandage. There is also a small risk of infection, delayed epithelial healing, corneal haze, or scarring.
For most patients, these short-term disadvantages are acceptable in exchange for the procedure’s established long-term record.

Epioxa: The New FDA-Approved Epithelium-On Treatment

Epioxa, developed by Glaukos, was FDA-approved in October 2025 and commercially available beginning in March 2026. The Epioxa treatment is performed without removing the corneal epithelium. This is appealing because the intact epithelial layer protects the corneal surface, potentially making the procedure more comfortable and recovery easier.How Does Epioxa Work?

The challenge with epi-on cross-linking has always been getting enough riboflavin and oxygen into the corneal stroma. The epithelium is designed to protect the eye. Its tightly connected cells create a barrier that limits the penetration of substances, especially the very large riboflavin molecule. The main Epioxa difference is they use an oxygen mask over the eye.

Specialized riboflavin formulations: Two riboflavin solutions are designed to improve delivery through the intact epithelium.
Surface preparation: The mucin layer is gently removed without intentionally removing the epithelial cells.
Supplemental oxygen: Oxygen-delivery goggles increase oxygen availability at the corneal surface.
Pulsed UVA illumination: A specialized ultraviolet light system alternates between illumination and rest periods, helping support the oxygen-dependent cross-linking reaction.

These advances are designed to overcome the limitations that historically made epi-on cross-linking less effective than epi-off treatment.

What Do Clinical Studies Show?

Epioxa received FDA approval based on randomized, controlled Phase 3 clinical studies demonstrating statistically significant improvements in maximum corneal curvature compared with sham treatment. In October 2026, Glaukos also announced encouraging three-year follow-up results suggesting sustained corneal stability and a favorable safety profile. However, it is important to distinguish between demonstrating that a treatment works and proving that two different treatments have equivalent long-term effectiveness.

Epioxa’s trials showed that it may be better than no treatment at all, but its trials did not show that it is equivalent or superior to traditional epi-off cross-linking. Traditional epi-off treatment also has a substantially longer published history of follow-up. As additional Epioxa data become available, ophthalmologists will be better able to determine which patients benefit most from each approach.

Epi-On vs. Epi-Off: How Do They Compare?

Feature                                                   Traditional Epi-Off                                                                         Epioxa Epi-On
Epithelial removal                                             Yes                                                                                                     No
Riboflavin delivery.                        Direct stromal penetration                                Specialized formulations through intact epithelium
UVA treatment                                   Established protocols                                                      Oxygen-enriched, pulsed UVA
Discomfort                                        Usually greater initially                                                                    Generally less
Initial healing                                        Typically 3–5 days                                                          No intentional epithelial wound
Long-term evidence                           More than a decade                                              Emerging, including reported 3-year results
FDA-approved option            Yes, specific drug/device protocol                                          Yes, specific drug/device protocol
Cost and coverage                     Varies by protocol and insurer                                    Newer, high-cost drug with evolving coverage

Neither procedure should be considered automatically best for every patient. Corneal thickness, age, disease progression, severity, and individual circumstances all matter. For example, the standard FDA-approved epi-off protocol generally requires a minimum corneal thickness of 400 microns after epithelial removal and before irradiation. Epioxa’s labeled protocol specifies a minimum of 325 microns with the epithelium intact. These measurements are not directly interchangeable, and treatment of thin corneas requires careful evaluation.

What Does Corneal Cross-Linking Cost?

Cost is one of the most important and most confusing aspect of this treatment. The cost depends on the treatment protocol, the practice, insurance contracts, and whether the treatment is considered medically necessary-which usually requires progression…which is what the treatment is trying to prevent. This is super important!

Traditional Epi-Off Cross-Linking

At SHARPEVISION, our self-pay epi-off cross-linking option with the Peschke device is $2,500 per eye as of this writing, although patients should confirm current pricing and exactly what is included. Our approach bypasses the dense maze of insurance, usually with less out of pocket than third party payers that may delay or deny your treatment. Traditional epi-off cross-linking can be performed using different riboflavin formulations and devices. Not every protocol is identical to the specific FDA-approved Photrexa/KXL combination. Patients should understand which treatment protocol is being offered and its regulatory status.

Epioxa and Its Higher Medication Cost

Epioxa introduces a very different economic model. The proprietary riboflavin medication is considerably more expensive than many conventional cross-linking drug preparations. Published pricing discussions have placed the Epioxa drug kit at approximately $78,500 before negotiated discounts or reimbursement arrangements. That figure is a pharmaceutical list-price benchmark—not necessarily the amount paid by an insurer, physician, or patient. The patient’s actual financial responsibility can be dramatically different. Nevertheless, a high medication price can have consequences for patients with deductibles, coinsurance, coverage restrictions, or limited insurance benefits.

Does Insurance Cover Cross-Linking?

Many medical insurance plans recognize corneal cross-linking as medically necessary for progressive keratoconus-meaning it must get worse. Requirements may include documented changes in corneal curvature, worsening astigmatism, deterioration in vision, or other evidence of progression. Coverage is not universal, and policies differ substantially. Some plans require prior authorization. Others impose age restrictions, specific progression criteria, or limitations on which medications and procedures qualify. Epioxa now has its own permanent HCPCS medication billing code, J2789, effective July 1, 2026. The cross-linking procedure itself is generally reported under CPT code 0402T. Having billing codes, however, does not guarantee insurance coverage or payment.

Why Could an Insured Patient Pay More Out of Pocket?

It seems counterintuitive, but insurance coverage does not always mean that a treatment is less expensive for the patient. Consider two hypothetical situations:

Patient A: Traditional Epi-Off Cross-Linking
The patient chooses a self-pay treatment costing $2,500 per eye. The cost is known in advance, and the patient can plan accordingly.

Patient B: Epioxa Through Insurance
The patient has insurance coverage but has not met their deductible and is responsible for a portion of the covered treatment cost. Depending on the insurer’s negotiated rate, deductible, coinsurance, and annual out-of-pocket maximum, the patient could potentially owe more than the $2,500 self-pay alternative. Of course, the reverse may also be true. Some patients may have excellent insurance benefits and pay less for Epioxa. Glaukos also offers a patient assistance and copay support program for eligible commercially insured patients, potentially reducing their costs considerably.

The critical point is that insurance coverage, medication list price, and actual patient out-of-pocket cost are three very different things. Patients should request an individualized financial estimate rather than assume that an insurance-covered procedure will be their least expensive option.

Why SHARPEVISION Continues to Offer Epi-Off Cross-Linking

As of this writing, at SHARPEVISION, we monitor technology and evaluate all advances in our field. Epioxa in my opinion hasn’t yet proved itself worthy of adoption in our practice. Keratoconus can lead to blindness. The time-tested epi-off treatment is harder to recover from, but the risk to benefit ratio in my opinion is currently better than Epioxa. Add in the cost and barriers that third party payers create, I think the best thing for patients is still epi off. If a patient has less severe disease, Epioxa may be a reasonable option, followed by periodic monitoring of the condition. Cross linking can be repeated if progressive.

Our decision to continue offering epi-off cross-linking reflects several priorities:

• Providing effective treatment supported by long-term clinical experience.
• Helping patients avoid unnecessary delays while keratoconus progresses.
• Offering transparent pricing and discussing financial options before treatment.
• Considering both the clinical and economic consequences of treatment choices.

We believe innovation should improve access to care, not unintentionally create new financial barriers. For patients who qualify for Epioxa treatment through their insurance, the shorter recovery may be particularly attractive. For others, traditional epi-off treatment may offer a more practical combination of established effectiveness and predictable cost.

When Should Keratoconus Be Treated?

One of the most important lessons of treating keratoconus is that waiting too long can risk irreversible vision damage. Cross-linking is most valuable before substantial corneal distortion or scarring develops. Patients as young as teenagers may experience rapid progression, and may need early intervention.  The decision is made using corneal topography, pachymetry, refraction, age, clinical history, and evidence of progression. The goal is to preserve useful vision over a patient’s lifetime.

The Bottom Line: Protecting Vision Comes First

Epioxa is now approved to perform cross-linking without intentionally removing the epithelium. Traditional epi-off cross-linking, meanwhile, remains a proven treatment with a longer history of successful clinical outcomes. At SHARPEVISION, we believe the right treatment decision should consider the strength of the clinical evidence, the individual patient’s corneal condition, recovery expectations, insurance coverage, and actual out-of-pocket expense. Our goal is simple: help patients with keratoconus preserve their vision through effective, timely, and financially accessible treatment.

If you or a family member has been diagnosed with keratoconus, schedule a consultation with SHARPEVISION where we perform corneal imaging, monitor disease progression, review all the data with you individually, discuss cross-linking options, and treatment costs.

Medical disclaimer: This article is for educational purposes and does not replace an individualized examination or medical advice. Treatment availability, insurance coverage, and pricing are subject to change.